Sisram Medical Celebrates Major Milestone with DAXXIFY Launch
Introduction of DAXXIFY in Mainland China
Marking the introduction of the world's first and only peptide-powered botulinum toxin product to Mainland China
Sisram Medical, a leading innovator in the medical aesthetics field, has recently announced an exciting breakthrough in its injectable botulinum toxin line. The National Medical Products Administration has accepted the Biologics License Application for DAXXIFY, a revolutionary product that aims to improve the appearance of moderate to severe glabellar lines. This innovative treatment combines botulinum toxin with proprietary Peptide Exchange Technology to achieve exceptional outcomes.
Understanding DAXXIFY Benefits
DAXXIFY’s results can be visible as soon as the next day and generally within two days. Designed for longevity, it helps maintain smooth skin with the benefit of as few as two treatments per year, with effects gradually softening over time. Users also report improved skin texture, addressing even the most stubborn wrinkles, making it a sought-after option for those focused on aesthetic enhancement.
Safety and Storage Advantages
In addition to its efficacy, DAXXIFY stands out for its safety profile. It is free from human albumin and animal-based components, minimizing the risk of neutralizing antibodies and allergic reactions. Furthermore, it is convenient for practitioners as it can be stored at room temperature, with specific reconstitution storage requirements that keep it effective for three days under refrigeration.
Sisram's Growth Through Strategic Approaches
The registration of DAXXIFY marks a significant milestone for Sisram Medical, enhancing its injectable business and supporting a comprehensive wellness ecosystem. The company is well-positioned to commercialize this innovative product in China's dynamic market.
Collaborative Agreements Expanding Reach
Along with the approval, Sisram has established a license agreement granting exclusive rights for importing and selling DAXXIFY in Mainland China, Hong Kong SAR, and Macao SAR. The company also partners with IBSA for dermal biostimulator products and Prollenium for well-regarded dermal fillers, aiming to broaden its reach and enhance its portfolio in various Asian markets.
A Robust Market for Injectables in China
The injectable market in China has seen a dramatic rise, estimated to be valued at RMB33.3 billion. This incredible growth provides Sisram with a competitive edge, presenting new revenue opportunities and solidifying its foundation for future business endeavors in the region.
Leadership's Vision for the Future
Mr. Liu Yi, Chairman and Executive Director of Sisram, highlighted China's strategic importance, stating that the approval for DAXXIFY reflects their commitment to bringing high-quality products to the market. CEO Lior Dayan echoed this sentiment, emphasizing the importance of enriching patient experiences and supporting practitioners with effective solutions that align with modern aesthetic demands.
About Sisram Medical Ltd
Sisram Medical Ltd is recognized as a global consumer wellness group that offers a unique ecosystem of products and services in various areas, including energy-based devices, injectables, and more. The company is a majority-owned subsidiary of Fosun Pharma, a significant player in the healthcare market in China. Sisram Medical made its public debut on the Hong Kong Exchange in 2017, emphasizing its commitment to enhancing lives through innovative solutions in aesthetics.
Frequently Asked Questions
What is DAXXIFY?
DAXXIFY is a novel botulinum toxin product designed to improve the appearance of glabellar lines and enhance skin texture.
How does DAXXIFY differ from other injectables?
DAXXIFY utilizes Peptide Exchange Technology, making it unique in enhancing efficacy and providing longer-lasting results.
What are the storage requirements for DAXXIFY?
DAXXIFY can be stored at room temperature and, once reconstituted, should be refrigerated for up to 72 hours.
Who owns Sisram Medical?
Sisram Medical is primarily owned by Fosun Pharma, a leading healthcare group in China.
When was Sisram Medical listed on the stock exchange?
Sisram Medical was publicly listed on the Hong Kong Exchange in September 2017.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.